Skip to main content
TipRanks
Go Ultimate75% OFF

Centene (QEN) Stock Price & Analysis

0 Followers

QEN Stock Chart & Stats

No data to display
Day’s Range
N/A
52-Week Range
N/A
Previous Close
N/A
Volume
N/A
Average Volume (3M)
N/A
Market Cap
CHF 28.92B
Enterprise Value
CHF 46.34B
Total Cash (Recent Filing)
CHF 23.59B
Total Debt (Recent Filing)
CHF 15.54B
Price to Earnings (P/E)
23.8
Beta
0.78
Next Earnings
Feb 09, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Strong Revenue Growth

Rapid revenue expansion demonstrates strong demand across Centene’s government-sponsored and Marketplace businesses. Continued top-line growth can broaden operating scale, support investment in care-management capabilities, and provide a durable base for improving earnings if medical costs remain controlled.

Medicare Advantage Turnaround

Reaching Medicare Advantage breakeven earlier than planned signals meaningful improvement in pricing, utilization management, and execution. The expected move to better-than-breakeven results in 2027 could make the segment a more reliable contributor while Centene focuses growth on differentiated markets.

Debt Reduction

Substantial debt reduction improves financial flexibility and lowers interest expense, while eliminating near-term maturities reduces refinancing pressure. A stronger balance sheet gives Centene more capacity to fund growth, absorb medical-cost volatility, and pursue operational investments.

Bears Say

Volatile, Thin Profitability

Profitability has not yet demonstrated consistent durability despite strong revenue growth. The 2025 loss and low TTM operating margin indicate that medical utilization, execution, or other cost pressures can quickly erode earnings and limit the conversion of scale into shareholder returns.

Medicaid Membership Decline

Sustained Medicaid membership attrition can reduce premium revenue and operating scale in Centene’s largest business. Eligibility terminations and work requirements may also change member acuity, creating rate-alignment risk and making medical-cost performance harder to manage across future cycles.

PDP Margin Reset

The expected Part D margin reset shows that current segment profitability is not fully sustainable. Lower PDP margins could offset gains from enrollment growth and require continued cost-structure discipline, leaving consolidated earnings more dependent on performance in Medicaid, Marketplace, and Medicare Advantage.

Centene News

QEN FAQ

What is Centene’s market cap?
Centene’s market cap is CHF28.92B.
When is Centene’s upcoming earnings report date?
Centene’s next earnings report is estimated for Feb 09, 2027 (not yet confirmed), which is in 89 days.
How were Centene’s earnings last quarter?
Centene released its earnings results on Oct 27, 2026. The company reported CHF0.479 earnings per share for the quarter, beating the consensus estimate of CHF0.079 by CHF0.4.
Is Centene overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Centene pay dividends?
Centene does not currently pay dividends.
What is Centene’s EPS estimate?
Centene’s EPS estimate is -0.95.
How many shares outstanding does Centene have?
Centene has 495,068,000 shares outstanding.
What happened to Centene’s price movement after its last earnings report?
Centene reported an EPS of CHF0.479 in its last earnings report, beating expectations of CHF0.079. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of Centene?
Hedge funds hold Centene shares: the largest hedge-fund position in Centene is 1,395,384,046 shares, and hedge funds decreased their holdings by 3.1M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology